Panbela Therapeutics, Inc. Common Stock
PBLA
PBLA was delisted on the 6th of March, 2024.
0 hedge funds and large institutions have $0 invested in Panbela Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.
5.14% less ownership
Funds ownership: 5.14% → 0% (-5.1%)
100% less funds holding
Funds holding: 10 → 0 (-10)
100% less capital invested
Capital invested by funds: $564K → $0 (-$564K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$449K |
| 2 |
HF
HRT Financial
New York
|
-$34K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$31.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$14.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13.7K |
PBLA Hedge Fund Activity: Q1 2024 in Review
0 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q1 2024, worth a combined $0 — down 100% from $564K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PBLA and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Goldman Sachs, exiting entirely with an estimated $449K sold.
- 0 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q1 2024, down from 10 in Q4 2023.
- Funds reported $0 of Panbela Therapeutics, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q1 2024 and 10 closed out, a net change of -10 holders.
- The largest Panbela Therapeutics, Inc. Common Stock seller in Q1 2024 was Goldman Sachs, an estimated $449K sold.
Based on aggregated 13F filings for Q1 2024.